N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• patients with rheumatic heart disease undergoing single valve replacement

Exclusion Criteria:

• End stage renal disease (plasma creatinine concentration ≥ 300 µmol/L)

• Emergency cardiac surgery

• Planned off-pump cardiac surgery

• Chronic inflammatory disease on immunosuppression

• Chronic moderate to high dose corticosteroid therapy (≥ 10 mg/day prednisone or equivalent)

• Age ≤ 18 years.